INTRODUCTION
Eosinophilia is associated with many diseases, and it is characteristic of allergic and parasitic diseases (1, 2) .
It seems likely that eosinophils are protective in parasitic diseases, especially those due to helminths (3) (4) (5) , but its role in allergic diseases is speculative. We have studied a protein unique to eosinophils, the major basic protein (MBP)' (6) (7) (8) , which constitutes 50%o of the total granule protein of the eosinophil and accounts for -25% of all protein within the cell (6, 9) . The MBP is a strongly basic molecule with a molecular weight of 9,300 in the human (8) and 11,000 in the guinea pig (7) . The MBP exists within the crystalloid core ofthe eosinophil granule (10) , and it is released to the exterior of the cell during degranulation (11) (12) (13) (14) . MBP differs from Charcot-Leyden crystal protein in its molecular weight and amino acid composition (8) . Purified MBP damages schistosomules of Schistosoma mansoni (11) and newborn larvae of Trichinella spiralis (15) , and recently we have shown that it is toxic to a wide variety of mammalian tissue cells including tracheal epithelium (11, 16, 17) . Because the MBP has the ability to damage cells in vitro, and thus might cause damage in disease, we have developed a sensitive radioimmunoassay (RIA) to measure levels of human MBP in blood and other body fluids.
METHODS
Patient samples and normal controls. Patient sera used in these studies were obtained from individuals seen for medical treatment at either the Mayo Clinic or at the National Institutes of Health. Sera from normal individuals were obtained from volunteers donating blood to the Mayo Clinic Blood Bank. In the case of the normal controls, total eosinophil counts were performed using EDTA anticoagulated whole blood stained with Randolph's stain, and the cells were counted using standard cell counting chambers.
IAbbreviations used in this paper: DTT, dithiothreitol; ECP, eosinophil cationic protein; FCS, fetal calf serum; MBP, major basic protein; PPF buffer, 0.1 M Na2HPO4-KHRP04, pH 7.4, containing 1 mg/ml protamine sulfate and 0.5% FCS; RIA, radioimmunoassay. Purification of human eosinophil MBP. Human eosinophils were purified from leukocytes from a patient with eosinophilia, using a Haemonetics cell separator (Haemonetics Corp., Natwick, Mass.); 7 x 1010 leukocytes, 53% eosinophils, were present in the starting material. Erythrocytes were allowed to sediment in hydroxyethyl starch (Volex, McGaw Inc., Santa Ana, Calif.). Cells in the supernate were centrifuged at 200 g for 5 min, and the residual erythrocytes were lysed by treatment of the pellet with 4 ml of NH4Cl lysing buffer (8.29 g/liter NH4Cl, 1 .0 g/liter K2CO3, and 0.0372 g/ liter Na2EDTA) for each 1 ml of packed cells. After 2 min, the cells were centrifuged at 200 g for 5 min and resuspended in 100 ml RPMI-fetal calf serum (RPMI-1640, catalogue No. 380-2400, Gibco Laboratories, Grand Island Biological Co., Grand Island, N. Y., containing 10% heat-inactivated fetal calf serum [FCS] ). The method of Parrillo and Fauci (18) Methods for the purification of MBP from eosinophils are described in detail elsewhere (6) (7) (8) . Briefly, cells were washed in 0.25 M sucrose, disrupted by homogenization using six passes of the pestle in a Tenbroeck homogenizer (Kontes Glass Co., Evanston, Ill.), and centrifuged at 400 g to remove unbroken cells and larger particles. In these experiments, heparin was not added to the 0.25 M sucrose in the cell homogenization step, because in preliminary experiments we had found it could be eliminated in most cases. The supernate was centrifuged at 13,000 g for 20 min; the sediment was dissolved in 0.01 M HCI and fractionated on a column of Sephadex G-50 equilibrated with 0.025 M CH3CO2H-CH3-CO2Na, pH 4.3. After purification, the MBP was stabilized by alkylation of its two sulfhydryl groups. EDTA at a final concentration of 0.002 M and dithiothreitol (DTT) at a 60-fold molar excess above available sulfhydryl groups were added to the MBP at pH 8.0 and the mixture was incubated at room temperature for 40 min. lodoacetamide at a 120-fold molar excess was then added, and the mixture was incubated in the dark for 20 min. The reduced and alkylated sample was transferred to a 3,500-dalton cutoff dialysis casing (Spectrum Medical Industries Inc., Los Angeles, Calif.) and dialyzed overnight against 0.15 M NaCl. The concentration of human MBP was determined by absorbance at 277 nm, El'-cm = 26.3 (8) .
Antiserum to the human MBP. Freshly isolated MBP was mixed with an equal amount of crystalline rabbit serum albumin (Mann Research Laboratories, New York), and the resulting precipitate emulsified in complete Freund's adjuvant. Material containing 1 mg MBP was injected intradermally into rabbits at six lateral sites. 16 d and 6 wk later, the animals each received intradermally 1 mg MBP emulsified in complete Freund's adjuvant. 17 wk after the initial immunization, the animals were given three injections of0.5 mg MBP in saline, subcutaneously on day one and intravenously on days two and three. 13 wk later the animals received another series of three injections identical to those above. The animals were exsanguinated 2 wk after the final immunization, and the antiserum was stored at -20°C.
RIA for human MBP. Reduced and alkylated human MBP was radioiodinated with 131 I by a modification ofthe procedure described by McConahey and Dixon (19) . Approximately 600 ,uCi of 1311, diluted in 200 ,ul of 0.5 M Na2HPO4-KH2PO4, pH 7.5, was added to a plastic tube on ice followed by 10 ,ug of reduced and alkylated MBP in 25 1,u PPF buffer (0.1 M Na2HPO4-KH2PO4, pH 7.4, containing 1 mg/ml protamine sulfate and 0.5% FCS). Chloramine T, 25 ,ul of 1 mg/ml in 0.5 M phosphate buffer, was added and mixed intermittently for 3 min. Sodium metabisulfite, 25,ul of 1 mg/ml, was added, and the mixture was incubated for another 2 min, after which 50 ,l of 1% KI was added and the contents of the tube thoroughly mixed. Next, 3 ml of PPF buffer was added, and the contents transferred to a 3,500-dalton cutoffdialysis casing and dialyzed against four changes of0. 15 M NaCl. Aliquots of131I-MBP were frozen, and 1 ,g/ml working stock was stored at 4°C. Specific activity ranged from 25 to 30 ,uCi/,ug and >98% ofcounts were precipitated by 10% tungstic acid. Details for performing the RIA are similar to those described elsewhere for measurement ofguinea pig MBP (20) . Briefly, 0.1 ml of a 1: 10,000 dilution of rabbit anti-human eosinophil MBP in PPF buffer, 0.5 ml of PPF buffer, and 0.1 ml of the sample to be tested were added to 10 x 75-mm glass tubes. The contents were thoroughly mixed, incubated at 37°C for 30 min and at 4°C for 15 min, and 1 ng 131I-MBP diluted in 0.1 ml PPF buffer was added. The tubes were covered and incubated overnight at 4°C. Immune complexes were precipitated by addition of0.1 ml of 1:20 dilution of normal rabbit serum in PPF buffer and 0.1 ml of burro anti-rabbit IgG. Tubes were mixed, incubated at 4°C for 2 h, and centrifuged for 20 min at 4°C and 2,500 g. The supernates were discarded, the tubes drained, and the precipitate counted in a Nuclear Chicago gamma scintillation counter (Nuclear Chicago Corp., Des Plaines, Ill.). Controls containing 100%o of the 131I-MBP added to each tube were counted for a sufficient time to accumulate 10,000 counts or more; assay tubes were counted for an equal time and expressed as a percentage of total counts bound. At a dilution of 1:10, anti-MBP bound 77.6% of 31I-MBP; an antiserum titration curve is shown in Fig. 1 Antiserum dilution lo-6
FIGuRE 1 Antiserum titration curve of rabbit antiserum to human eosinophil MBP. The titration used 0.1 ng '31I-MBP in 0.6 ml PPF buffer reacted with 0.1 ml of antiserum at increasing dilutions at 4°C. After overnight incubation, 0.1 ml of normal rabbit serum diluted 1:20 in PPF buffer and 0.1 ml of burro anti-rabbit IgG were added. The tubes were mixed and incubated for 2 h at 4°C. The percentage of counts in the precipitate is plotted on the ordinate, and the reciprocal of the antiserum dilution is plotted on the abscissa.
data from repetitive freeze-thaw cycles are shown in Table I .
Fractionation of serum by gel filtration. The molecular weight of MBP in blood was estimated by gel filtration ofboth untreated serum and serum that had been reduced and alkylated. In the case of untreated serum, -125 mg of serum protein, as determined by biuret analysis, was diluted with 0.01 M Na2HPO4-KH2PO, and 0.2M NaCl, pH 7.4, and applied to a 5 x 87-cm Sephadex G-200 column equilibrated with the diluent buffer. The column flow rate was -21.3 ml/h. Fractions of 7.3 ml were collected and the absorbance at 277 nm was determined. Samples ofthese fractions were then reduced and alkylated as described above and assayed for MBP activity by RIA.
In other experiments, the serum sample was first diluted with two parts of PPF buffer and then reduced and alkylated as described above. The pH was lowered to pH 1.5 by addition of 2 M HC1, and the sample applied to a 1.2 x 45-cm Sephadex G-50 column equilibrated with 0.01 M HC1-0.15 M NaCl. The column flow rate was -30 ml/h. Absorbance at 277 nm of 1-ml fractions was measured, and fractions were assayed by RIA for MBP activity.
RESULTS

Specificity and optimal conditions for the RIA
In initial RIA experiments the specificity and the optimal conditions for measurement of MBP were de- 12 * Internal controls were tested each time that an RIA was performed. Aliquots of a single high MBP serum and a single low MBP serum were stored over an 18-mo period at -20°C, and after reduction and alkylation they were assayed independently in 45 different assays. The possibility that the serum MBP levels changed during the 18-mo period was tested by regression analysis. The correlation coefficients for the relationship between time and level of MBP in the high and low sera, respectively, were +0.12 (NS) and -0.64 (P < 0.001). The mean+SD for the first 10 analyses of the lower MBP serum was 476±82, whereas the mean for the last 10 analyses was 320±79. were produced with each of the several patient sera tested. However, reduction and alkylation, as well as acidification to pH 2, were required to separate monomeric MBP from other serum proteins, and the amount of MBP separable from the void volume peak was highly sensitive to experimental conditions. An alteration in DTT concentration or failure to lower the pH to 2 resulted in lower amounts of total MBP activity present in the monomeric form. Acidification alone did not result in the release of monomeric MBP into the serum, in that all of the MBP activity eluted in the void volume. Finally, even when reduced, alkylated, and radiolabeled MBP is added to serum and passed over the Sephadex G-50 column at pH 6.6, 78% of the MBP activity elutes in the void volume peak and only 22% in the expected position for the MBP monomer. The experiments described above established that sera must be reduced and alkylated before RIA to reveal their maximal MBP content. To determine the efficiency ofthis procedure, known amounts ofreduced MBP were added to sera and the recoveries determined in two experiments. The results in Table III with DTT prior to addition to sera; 10,000 ng was added to sera 1 through 6. In both experiments the quantity of MBP added was based on absorbance at 280 nm using El"cm = 26.3.
reduced and alkylated and assayed for MBP activity. As shown in Fig. 3 described above indicate that in sera from patients with eosinophilia, monomer MBP activity can be demonstrated by gel filtration after reduction, alkylation, and acidification. As shown in Table II , MBP activity found in normal serum also increased after reduction and alkylation; the MBP activity in normal sera produced inhibition curves identical in shape to those shown in Fig.  4 . However, numerous attempts to demonstrate monomer MBP in normal sera by reduction, alkylation, and acidification and separation on Sephadex G-50 were unsuccessful. This finding raised the question of whether or not the MBP activity in normal serum represented specific MBP or resulted from nonspecific inhibition due to interference from other proteins in the RIA. To help answer this question, we tested whether sera from other species or high concentrations of serum proteins would produce inhibition in the RIA after re-55. duction and alkylation. We found little or no inhibition in these samples, and if MBP activity was present, levels never exceeded 30 ng/ml. Additionally, we analyzed sera before and after heating. The results in Table IV indicate that the activity of the purified, reduced, and alkylated MBP standard is destroyed by heating, in keeping with similar results for guinea pig MBP (20) . In serum with elevated MBP activities, about half of this activity is lost, provided that the serum is heated after reduction and alkylation; if patient serum is heated before reduction and alkylation, MBP activity is unaltered. In normal serum, MBP activity is unchanged by heating regardless of whether it is heated before or after reduction and alkylation. Therefore, although it appears that normal individuals show low levels of circulating MBP in their blood, we cannot eliminate the possibility that the levels ofactivity measured in such samples might be due to nonspecific factors. ,uI serum FIGURE 4 Inhibition curves in the RIA of MBP standard and serum after reduction and alkylation. MBP activity was measured in reduced and alkylated human serum (-) and compared with the inhibition curve given by reduced and alkylated MBP standard (0). The human serum was obtained from a patient with the hypereosinophilic syndrome and was reduced and alkylated before assay as described in Methods. Statistical analysis of the logit-log transformed data revealed that the null hypothes,is of a common slope could not be rejected (F,,g = 1.844; NS).
MBP levels in patient and normal control sera
Because reduction and alkylation are necessary for optimal recovery of MBP activity both in normal and patient serum, we reduced and alkylated sera before analysis in the RIA. The shapes of inhibition curves given by serum MBP and by the MBP standard are essentially identical, as shown in Fig. 4 . The coefficient of variation for the RIA is 23% and the high MBP serum showed no decline in activity. However, the low MBP serum sample showed a significant loss of activity with time (P < 0.001) ( Table I) . Repetitive freeze-thawing of patient sera resulted in no decline of MBP activity.
Serum levels of MBP activity and total eosinophil counts were performed on samples from 105 healthy 5A ). However, a significant correlation exists between eosinophil counts and serum MBP levels in patients with eosinophilia (Fig. 5B) . Values of serum MBP activity in normal patients ranged from 320 to 800 ng MBP/ml (mean, 454 ng MBP/ml), whereas values from patients with eosinophilia were usually elevated and ranged as high as 14,400 ng MBP/ml (Table V) . Thus, patients with elevated levels of blood eosinophils tend to have parallel elevations of MBP. Normal values for eosinophil counts (<350/mm3) and serum MBP levels (<600 ng/ml) are based on the values obtained from a sample of 105 such controls; 95% of these normal individuals had values below figures given. Serum levels of MBP and peripheral blood eosinophil counts for 188 patients and 105 normal controls are summarized in Table V . Patients were grouped by diagnosis into categories based on major organ involvement or generalized disease process. Although the categories chosen are somewhat arbitrary, examination of the data in this form permits comparison of the relationships among major disease categories. Great variation exists among patients' eosinophil counts and levels of serum MBP, even when they share a common diagnosis. For example, patients with asthma showed eosinophil counts ranging from 0 to 13,000/mm3 and MBP activities ranging from normal (<600 ng/ml) to 2,560 ng MBP/ml serum. The highest eosinophil counts and highest levels of serum MBP were seen in patients with the hypereosinophilic syndrome (21) . These patients averaged almost 5,000 ng MBP/ml serum with levels as high as 14,400 ng/ml. Several patients with hypereosinophilic syndrome were receiving steroid therapy and their disease was under control. These patients showed slightly elevated eosinophil counts and normal or only slightly elevated levels of serum MBP. In addition, normal levels of MBP activity were found in renal transplant patients receiving immunosuppressive drugs, including prednisone, whose bloods were devoid of eosinophils.
Remarkably, a significant proportion of patients with skin disease showed elevated levels of MBP in the absence of peripheral blood eosinophilia. Of 16 patients with chronic urticaria, none showed eosinophil counts > 280/mm3, yet 6 of these patients (38%) showed elevated levels of MBP (>600 nglml). Of all 88 patients with skin disease tested, 20 (22%) showed normal eosinophil counts but elevated levels of MBP Table I , freeze-thawed samples assayed in the same experiment had coefficients of variation of 9-12%. The difference between the intraassay coefficient of variation of 9-12% (using the results from the freeze-thaw experiment) and the interassay value of23% presumably is due to the reduction and alkylation procedure, which must be employed to recover MBP activity (as shown by the results in Table III ).
In the guinea pig we found that normal sera and sera from animals infected with T. spiralis contained <5 ng/ml MBP. In humans, both normal sera and sera from patients with eosinophilia contain considerably higher levels of MBP activity. Whether the MBP activity in normal human serum represents specific MBP is ambiguous; however, reduction and alkylation increased the MBP activity in normal sera and these inhibition curves parallel that of the MBP standard. Furthermore, if the inhibition produced by normal serum were nonspecific and due to competition between antibody and serum protein for radioiodinated MBP, one would expect the sera of other species such as guinea pig and newborn calf to give comparable inhibition. Contrary to this prediction, these controls produced little inhibition. Thus, the present results support but do not prove that MBP is present in normal sera.
In sera from patients with eosinophilia, MBP is bound to serum proteins in the 4S, 7S, and 19S peaks from Sephadex G-200 gel filtration. To release MBP from these carrier proteins, serum must be reduced and alkylated and acidified with HC1 to a pH of 2. Under these conditions, as much as 80% of the MBP activity can be isolated from the major serum proteins by passage over Sephadex G-50 at pH 2.0. Gel filtration and preparative electrofocusing experiments indicate that the bulk of the MBP in serum is not a simple polymer of the molecule itself, but rather is bound to a larger carrier. Because reduction and alkylation are required to release the MBP, presumably it is covalently bound to carrier protein molecules. The experiments testing the recovery of reduced MBP from serum highlight the need for reduction and alkylation prior to assay (Table III) .
Serum levels of MBP show no correlation with eosinophil counts in normal subjects, but show a significant positive correlation in patients with eosinophilia. Patients who had received renal transplants and who were treated with glucocorticoids and immunosuppressive drugs showed no detectable eosinophils in the peripheral blood, yet still possessed MBP activity in the serum. The marked increase in MBP activity present in serum from patients with eosinophilia is specific, as we have separated MBP from such samples. Eosinophil counts from the 188 patients in our sample (exclusive ofnormal controls) varied widely and ranged from 0 to 48,400/mm3, whereas serum levels of MBP ranged from 239 to 14,400 ng/ml. Patients with normal eosinophil counts (<350/mm3) generally had levels of serum MBP in the normal range (<600 ng/ml), and patients with peripheral blood eosinophilia generally showed parallel increases in serum MBP. For example, 80% of all patients with eosinophilia (>350/ mm3) showed MBP levels in excess of 600 ng/ml. Of the patients with normal eosinophil counts, 68% showed levels of MBP in the normal range; of the remaining 32% of these patients, who showed increased MBP Researchers in Sweden (22-25) have also described eosinophil cationic proteins (ECP) and have measured levels ofthese proteins in the serum of normal subjects and in patients with asthma. The ECP described by Olsson et al. (22, 23) is about twofold larger in molecular weight than the MBP and differs from the MBP in amino acid composition. They estimate that the ECP accounts for -30% of the granule protein (23) . In contrast, the MBP has been localized to the crystalloid core of the granule of the guinea pig and accounts for >50%o of the granule protein (6, 10) . Although it seems unlikely that the two proteins are structurally related, their relationship has not been defined. Venge et al. (24, 25) measured levels of ECP in the serum ofhealthy individuals and found a direct correlation between the eosinophil count and the serum levels of ECP. They further found unexpectedly low levels of ECP in serum from patients with asthma. These findings contrast with those described in our studies, where no correlation was found of eosinophil counts with serum MBP in healthy subjects and elevated levels of MBP in the serum of most asthmatics with eosinophilia. The conditions used by Venge and his colleagues (24) to isolate ECP from serum were not effective in our laboratory when applied to isolation of MBP from serum.
Monomer MBP is cytotoxic to parasites (11, 15) and mammalian cells (11, 16, 17) , and the findings of elevated levels of serum MBP indicate that eosinophils are releasing granule contents into the circulation. The highest concentrations of serum MBP were found in patients with the hypereosinophilic syndrome. If eosinophils degranulate in the vicinity of the endothelium ofblood vessels, it is possible that certain ofthe cardiovascular manifestations of the hypereosinophilic syndrome (26) could be due to damage to tissue by the release of eosinophil granule constituents.
